RAMM Pharma Corp. Announces Appointment of new Interim-Chief Financial Officer

Rhea-AI Summary

RAMM Pharma Corp. has appointed José Roldan as interim Chief Financial Officer, effective immediately, following Guillermo Delmonte's medical leave. Roldan, a public accountant with significant cannabis industry experience and a background with KPMG Uruguay, aims to enhance the company's financial oversight. RAMM Pharma, a leader in cannabinoid pharmacology, operates in Uruguay and Europe, focusing on cannabinoid pharmaceuticals and hemp-based products. The company is also developing a range of new products across various stages of approval.

Positive

• José Roldan brings extensive experience from KPMG, which may enhance financial management.
• RAMM Pharma operates in a growing industry with a diversified international production platform.

Negative

• The sudden departure of CFO Guillermo Delmonte may raise concerns about leadership continuity.
• The interim status of José Roldan might create uncertainties in long-term financial strategy.

TORONTO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), is pleased to announce the appointment of José Roldan as interim-Chief Financial Officer of the Company, effective immediately. Mr Roldan succeeds Mr. Guillermo Delmonte who is currently on medical leave.

Mr. Roldan is a Public Accountant specializing in audits of financial and commercial institutions. He has extensive experience in the cannabis space coupled with knowledge of central bank regulations and International Financial Reporting Standards. Prior to joining RAMM, Mr. Roldan worked as a senior auditor with KPMG Uruguay for six years.

About RAMM Pharma Corp.

RAMM Pharma is a leader in the field of cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other hemp-based products with a unique and diversified international production and sales platform. The Company operates an established pharmaceutical and medical product business in Uruguay that has developed several medically registered and approved plant-derived cannabinoid pharmaceutical products that have been authorized for sale and/or compassionate use in several Latin American countries. RAMM also has a pipeline of new products, including registered hemp-based nutrition and specialized veterinary products, in various stages of approval and development, which are produced at the company's state-of-the-art, good-manufacturing-practice-certified formulation facility in Montevideo, Uruguay.

In Europe, RAMM's vertically integrated operations are based in Ragusa, Italy and Elbląg, Poland (60 kilometres east of Gdańsk), and include a hemp cultivation platform, and large extraction and processing facilities (in the final stages of commissioning in the case of Canapar Corp.).

RAMM Pharma includes wholly owned subsidiaries Canapar Corp., HemPoland S.p.a. Z.o.o., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.

Additional information about the Company is available at www.rammpharma.com.

For further information, please contact:

Jimena Reyes
Executive Assistant
+598 2513 99 58
info@rammpharma.com

FAQ

Who is the new interim CFO of RAMM Pharma Corp.?

José Roldan has been appointed as the interim CFO of RAMM Pharma Corp.

Why did RAMM Pharma appoint a new interim CFO?

José Roldan was appointed after Guillermo Delmonte took medical leave.

What experience does José Roldan bring to RAMM Pharma?

José Roldan has extensive experience in financial audits and the cannabis industry, previously working at KPMG Uruguay.

What impact could the management change have on RAMM Pharma?

The change in management could bring fresh perspectives but may also create uncertainties in financial strategy.

What does RAMM Pharma Corp. specialize in?

RAMM Pharma specializes in cannabinoid pharmacology and the formulation of cannabis-based pharmaceuticals.